Endurant Capital Management LP Amicus Therapeutics, Inc. Transaction History

Endurant Capital Management LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 15, 2019	SELL	$10.04 - $13.92 $584,729 - $810,700	-58,240 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$8.38 - $13.44 $104,984 - $168,376	-12,528 Reduced 17.7%	58,240 $558,000
Q3 2018 Nov 14, 2018	BUY	$11.6 - $16.54 $188,662 - $269,006	16,264 Added 29.84%	70,768 $856,000
Q2 2018 Aug 14, 2018	SELL	$13.13 - $17.09 $951,872 - $1.24 Million	-72,496 Reduced 57.08%	54,504 $851,000
Q1 2018 May 15, 2018	SELL	$13.76 - $17.12 $1.09 Million - $1.36 Million	-79,400 Reduced 38.47%	127,000 $1.91 Million
Q4 2017 Feb 14, 2018	BUY	$12.51 - $16.24 $2.58 Million - $3.35 Million	206,400	206,400 $2.97 Million

278

324M

260K

261K

Ticker FOLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 280,497,984
Market Cap $3B
Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...

Get notified when there are updates to the investment portfolio of Endurant Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Endurant Capital Management LP with notifications on news.